Bright Minds Biosciences (DRUG) Competitors

Nuvation Bio (NYSE:NUVB) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Do institutionals & insiders have more ownership in NUVB or DRUG?

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 29.9% of Nuvation Bio shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Do analysts prefer NUVB or DRUG?

Nuvation Bio currently has a consensus target price of $7.83, suggesting a potential upside of 210.23%. Bright Minds Biosciences has a consensus target price of $83.25, suggesting a potential upside of 194.48%. Given Nuvation Bio's higher possible upside, equities research analysts plainly believe Nuvation Bio is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Does the MarketBeat Community favor NUVB or DRUG?

Nuvation Bio received 47 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. However, 91.67% of users gave Bright Minds Biosciences an outperform vote while only 80.56% of users gave Nuvation Bio an outperform vote.

Company	Underperform	Outperform
Nuvation Bio	Outperform Votes 58 80.56%	Underperform Votes 14 19.44%
Bright Minds Biosciences	Outperform Votes 11 91.67%	Underperform Votes 1 8.33%

Which has more volatility & risk, NUVB or DRUG?

Nuvation Bio has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -5.75, suggesting that its share price is 675% less volatile than the S&P 500.

Is NUVB or DRUG more profitable?

Bright Minds Biosciences' return on equity of -5.85% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	N/A	-21.89%	-17.86%
Bright Minds Biosciences	N/A	-5.85%	-5.68%

Does the media refer more to NUVB or DRUG?

In the previous week, Nuvation Bio had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for Nuvation Bio and 2 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.90 beat Nuvation Bio's score of 0.60 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has higher valuation and earnings, NUVB or DRUG?

Bright Minds Biosciences has lower revenue, but higher earnings than Nuvation Bio. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$10.96M	78.41	-$75.80M	-$2.35	-1.07
Bright Minds Biosciences	N/A	N/A	-$2.06M	-$0.36	-78.53

Summary

Bright Minds Biosciences beats Nuvation Bio on 10 of the 17 factors compared between the two stocks.